Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To facilitate both better physician understanding of prognostic information (baseline and with adjuvant interferon) for individual patients who present with resectable melanomas and more informed patient decisions about whether they should receive adjuvant high-dose interferon therapy after resection of primary melanomas. Patients and Methods: Baseline survival estimates were derived from a surgical database composed of 17,600 patients with complete clinical, pathologic, and follow-up data. Potential survival benefits ascribed to adjuvant interferon were obtained from results of a meta-analysis of Eastern Cooperative Oncology Group studies, which provided evidence for a uniform relative benefit of high-dose interferon across different baseline risk groups. A mathematical formula was then applied to these data to allow for individual prognostic information. Results: The 5-year survival benefits in patients who received high-dose interferon after surgery, using the assumptions of the provided prognoses and interferon survival improvements, ranged up to 13%. Conclusions: These data should allow for a better understanding of baseline prognosis in individual patients and a better understanding of the potential benefits of adjuvant interferon. They should also help patients make more informed decisions regarding their treatment options.

Original languageEnglish (US)
Pages (from-to)913-917
Number of pages5
JournalMayo Clinic Proceedings
Volume77
Issue number9
StatePublished - 2002

Fingerprint

Interferons
Melanoma
Skin
Therapeutics
Survival
Meta-Analysis
Databases
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. / Thome, Stephan; Loprinzi, Charles Lawrence; Heldebrant, Michael P.

In: Mayo Clinic Proceedings, Vol. 77, No. 9, 2002, p. 913-917.

Research output: Contribution to journalArticle

@article{9cd0ea3d07bf4b1c9c04306c176d70c2,
title = "Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas",
abstract = "Objective: To facilitate both better physician understanding of prognostic information (baseline and with adjuvant interferon) for individual patients who present with resectable melanomas and more informed patient decisions about whether they should receive adjuvant high-dose interferon therapy after resection of primary melanomas. Patients and Methods: Baseline survival estimates were derived from a surgical database composed of 17,600 patients with complete clinical, pathologic, and follow-up data. Potential survival benefits ascribed to adjuvant interferon were obtained from results of a meta-analysis of Eastern Cooperative Oncology Group studies, which provided evidence for a uniform relative benefit of high-dose interferon across different baseline risk groups. A mathematical formula was then applied to these data to allow for individual prognostic information. Results: The 5-year survival benefits in patients who received high-dose interferon after surgery, using the assumptions of the provided prognoses and interferon survival improvements, ranged up to 13{\%}. Conclusions: These data should allow for a better understanding of baseline prognosis in individual patients and a better understanding of the potential benefits of adjuvant interferon. They should also help patients make more informed decisions regarding their treatment options.",
author = "Stephan Thome and Loprinzi, {Charles Lawrence} and Heldebrant, {Michael P.}",
year = "2002",
language = "English (US)",
volume = "77",
pages = "913--917",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas

AU - Thome, Stephan

AU - Loprinzi, Charles Lawrence

AU - Heldebrant, Michael P.

PY - 2002

Y1 - 2002

N2 - Objective: To facilitate both better physician understanding of prognostic information (baseline and with adjuvant interferon) for individual patients who present with resectable melanomas and more informed patient decisions about whether they should receive adjuvant high-dose interferon therapy after resection of primary melanomas. Patients and Methods: Baseline survival estimates were derived from a surgical database composed of 17,600 patients with complete clinical, pathologic, and follow-up data. Potential survival benefits ascribed to adjuvant interferon were obtained from results of a meta-analysis of Eastern Cooperative Oncology Group studies, which provided evidence for a uniform relative benefit of high-dose interferon across different baseline risk groups. A mathematical formula was then applied to these data to allow for individual prognostic information. Results: The 5-year survival benefits in patients who received high-dose interferon after surgery, using the assumptions of the provided prognoses and interferon survival improvements, ranged up to 13%. Conclusions: These data should allow for a better understanding of baseline prognosis in individual patients and a better understanding of the potential benefits of adjuvant interferon. They should also help patients make more informed decisions regarding their treatment options.

AB - Objective: To facilitate both better physician understanding of prognostic information (baseline and with adjuvant interferon) for individual patients who present with resectable melanomas and more informed patient decisions about whether they should receive adjuvant high-dose interferon therapy after resection of primary melanomas. Patients and Methods: Baseline survival estimates were derived from a surgical database composed of 17,600 patients with complete clinical, pathologic, and follow-up data. Potential survival benefits ascribed to adjuvant interferon were obtained from results of a meta-analysis of Eastern Cooperative Oncology Group studies, which provided evidence for a uniform relative benefit of high-dose interferon across different baseline risk groups. A mathematical formula was then applied to these data to allow for individual prognostic information. Results: The 5-year survival benefits in patients who received high-dose interferon after surgery, using the assumptions of the provided prognoses and interferon survival improvements, ranged up to 13%. Conclusions: These data should allow for a better understanding of baseline prognosis in individual patients and a better understanding of the potential benefits of adjuvant interferon. They should also help patients make more informed decisions regarding their treatment options.

UR - http://www.scopus.com/inward/record.url?scp=0036725295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036725295&partnerID=8YFLogxK

M3 - Article

C2 - 12233924

AN - SCOPUS:0036725295

VL - 77

SP - 913

EP - 917

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -